Board to consider FY18 results & Dividend on May 29, 2018
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018.... Board Meeting-Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018.... Board Meeting On May 29, 2018
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018.... Board Meeting On May 29, 2018
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, May 29, 2018, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2018 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2018.... Glenmark Pharma launches generic version of asthma drug in Denmark
Glenmark Pharmaceuticals Europe Ltd has launched a generic version of Seretide Accuhaler, used to treat asthma, in Denmark. The product was develope Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark announces grant of substitution and successful launch of generic Seretide Accuhaler in Denmark Glenmark Pharma gets USFDA nod for skin treatment cream
Glenmark Pharmaceuticals said it has received final approval from the US health regulator for the generic version of Temovate cream used to treat in Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Cream USP, 0.05% Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be presented at the International Investigative Dermatology Meeting Glenmark, Malpani Hospital clinical trial incident brings back ghosts from the past
More trials at the Jaipur hospital could come under CDSCO scrutiny